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ABSTRACT
Human papillomavirus (HPV) infection is the fastest growing cause of head and 
neck squamous cell carcinoma (HNSCC) today, but its role in malignant transformation 
remains unclear.  This study aimed to conduct a comprehensive investigation of PIWI-
interacting RNA (piRNA) alterations and functionalities in HPV-induced HNSCC.  Using 
77 RNA-sequencing datasets from TCGA, we examined differential expression of 
piRNAs between HPV16(+) HNSCC and HPV(–) Normal samples, identifying a panel 
of 30 HPV-dysregulated piRNAs.  We then computationally investigated the potential 
mechanistic significances of these transcripts in HPV-induced HNSCC, identifying our 
panel of piRNAs to associate with the protein PIWIL4 as well as the RTL family of 
retrotransposon-like genes, possibly through direct binding interactions.  We also 
recognized several HPV-dysregulated transcripts for their correlations with well-
documented mutations and copy number variations in HNSCC as well as HNSCC 
clinical variables, demonstrating the potential ability of our piRNAs to play important 
roles in large-scale modulation of HNSCC in addition to their direct, smaller-scale 
interactions in this malignancy.  The differential expression of key piRNAs, including 
NONHSAT077364, NONHSAT102574, and NONHSAT128479, was verified in vitro by 
evaluating endogenous expression in HPV(+) cancer vs. HPV(–) normal cell lines.  
Overall, our novel study provides a rigorous investigation of piRNA dysregulation in 
HPV-related HNSCC, and lends critical insight into the idea that these small regulatory 
transcripts may play crucial and previously unidentified roles in tumor pathogenesis 
and progression.
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 4), pp: 4614-4624
INTRODUCTION
Although tobacco use and alcohol consumption 
are the well-established and major risk factors for head 
and neck squamous cell carcinoma (HNSCC), high-risk 
human papilloma virus (HPV) infection, primarily due 
to HPV16, is quickly emerging as the fastest growing 
cause of the disease [1]. Over the past few decades, 
the proportion of HPV-associated HNSCCs has steadily 
risen to comprise 10–30% of all cases of HNSCC, while 
specific subtypes including oropharyngeal squamous 
cell carcinoma (OPSCC) display a corresponding 
proportion of around 40–80% [1].  Recent studies have 
suggested HPV infection to increase risk of HNSCC up 
to 22-fold [2].
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Despite the prevalence of HPV-associated 
HNSCC, current knowledge of its molecular mechanism 
of pathogenesis and progression is limited. After 
demonstration of the carcinogenic role of HPV in HNSCC 
in 2000 [3], studies have implicated HPV16 E6/E7 gene 
expression in promoting malignant transformation in 
HNSCC [4]. The over-expressed E6 onco-protein caused 
by HPV16 is able to induce degradation of the tumor 
suppressor protein p53 via the ubiquitin pathway [4]. At 
the same time, E7 onco-protein can bind and inactivate 
the retinoblastoma (Rb) tumor suppressor gene product, 
promoting cell G1-S phase transition [4]. Aside from the 
effects of E6/E7 on these tumor suppressors, HPV-induced 
alterations in other factors, including genomic stability 
and epigenetics, are also known to play critical roles in 
malignant transformation and tumor progression.
Advances in the understanding of non-coding RNAs 
(ncRNAs) have revealed their active involvement in a 
myriad of biological processes including transcriptional 
and post-transcriptional regulation. Non-coding RNAs 
have also been implicated in a number of cancers [5–7]. 
As the largest class of small non-coding RNAs, PIWI-
interacting RNAs (piRNAs) are thought to function in 
cells by forming piRNA/PIWI protein complexes that 
promote retrotransposon silencing and post-transcriptional 
regulation [8, 9]. Interestingly, our previous study on the 
non-coding landscape of HNSCC indicated that piRNAs 
dysregulated in HNSCC may have associations with 
different etiological factors [10]. Our follow-up study on 
smoking-induced piRNA alterations identified a novel 
panel of piRNAs specifically associated with smoking-
induced HNSCC [11]. Therefore, in this study, we 
attempted to comprehensively analyze the HPV-associated 
piRNA landscape of HNSCC.
Using 77 HPV16(+) and HPV(–) RNA-seq datasets 
from the Cancer Genome Atlas (TCGA), we identified 
HPV-specific piRNA dysregulation in HNSCC. We then 
analyzed the mechanistic and clinical relevancies of these 
piRNAs in HPV-induced head and neck malignancies to 
evaluate their overall functional significances in tumor 
pathogenesis and progression.
RESULTS
Identification of HPV-dysregulated piRNAs in 
HNSCC
In order to identify HPV-associated piRNAs in 
HNSCCs, we examined 77 HPV16(+) HNSCC and 
HPV(–) Normal RNA-seq datasets from TCGA with 
available clinical data (dataset IDs in Supplementary 
Table 1).  We used negative-binomial based differential 
expression testing to perform 2 comparisons of piRNA 
expression between HPV16(+) and HPV(–) cohorts, 
separately analyzing smoking and nonsmoking datasets as 
smoking has been suggested to independently alter piRNA 
expression in HNSCC (Figure 1) [11] . We identified 58 
piRNAs to be dysregulated between HPV16(+) HNSCC 
Smokers and HPV(–) Normal Smokers and 39 piRNAs to 
be dysregulated between HPV16(+) HNSCC Nonsmokers 
and HPV(–) Normal Nonsmokers (FDR < 0.05, 
Supplementary Table 2). The differential dysregulation 
of piRNAs due to HPV in smoking and nonsmoking 
backgrounds is displayed in Figure 2.
In order to perform a robust identification of HPV-
altered piRNAs, we selected only piRNAs dysregulated 
in both comparisons to include in our panel of HPV-
dysregulated transcripts, identifying 30 such candidates 
(Figure 1, Supplementary Table 2).
Associations of HPV-dysregulated piRNAs with 
PIWI proteins
piRNAs are thought to execute their functionality 
by associating with PIWI proteins, forming PIWI-piRNA 
complexes that promote gene silencing [12]. Therefore, 
utilizing gene set enrichment analysis (GSEA), we 
attempted to identify PIWI protein candidates that may 
potentially associate with piRNAs in HPV-associated 
HNSCCs. Ranking 7385 piRNAs containing expression 
counts in at least one patient in order of positive to 
negative correlation with PIWI protein expression, we 
evaluated all piRNAs in our set of 30 HPV-dysregulated 
piRNAs for significant enrichment, separating upregulated 
(n = 24) and downregulated (n = 6) transcripts in order 
to match enrichment results to direction of dysregulation 
in cancer. We found our HPV-upregulated piRNA set 
to be positively enriched relative to PIWIL4 expression 
in HNSCC, suggesting a positive correlation between 
upregulated piRNAs expression and PIWIL4 expression 
(Figure 3A).
Potential regulation of the RTL family by HPV-
dysregulated piRNAs
Recent studies suggest that PIWI-piRNA complexes 
promote retrotransposon silencing either by targeting 
mRNA transcripts or mediating DNA methylation [12]. 
In order to more thoroughly understand the role of our 
HPV-dysregulated piRNAs in retrotransposon silencing, 
we decided to conduct a two-step analysis.
First, we assessed relationships between HPV-related 
piRNA expression and retrotransposon and retrotransposon-
like gene expression to identify potential targets of our 
piRNAs. Utilizing GSEA, we identified our set of HPV-
upregulated piRNAs to be significantly negatively enriched 
relative to the expression of various members of the 
retrotransposon-derived family RTL (FDR < 25%, Figure 
3B). This data suggests an inverse relationship between HPV-
dysregulated piRNA expression and RTL family expression, 
an expected result for piRNA-induced repression. Moreover, 
we identified our piRNAs to be positively enriched with 
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Figure 1: Schematic detailing the RNA-seq analysis pipeline used to identify HPV-associated piRNA candidates 
(p < 0.05, FDR < 0.05).
Figure 2: (A) Circos plot depicting piRNA expression in four cohorts: HPV(+) Cancer Smokers, HPV(–) Normal Smokers, HPV(+) 
Cancer Nonsmokers, and HPV(–) Normal Nonsmokers. (B) Similarities and differences in piRNA dysregulation in two comparisons: 
HPV(+) HNSCC Nonsmokers vs. HPV(–) Normal Nonsmokers and HPV(+) HNSCC Smokers vs. HPV(–) Normal Smokers. piRNA 
dysregulation is color-coded by fold change. Boxes with no color indicate that the piRNA was not found dysregulated in that comparison.
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respect to the expression of DNMT3L, a protein essential 
for both proper transposon methylation and repression [13], 
suggesting that piRNA-induced repression may be potentially 
mediated by a methylation-related mechanism, as mentioned 
above (Figure 3C). 
Next, to verify the potential of our piRNAs to 
directly silence these genes, we explored the presence of 
direct binding interactions between specific piRNAs and 
RTL family members. Employing the miRanda algorithm, 
we determined all GSEA-identified RTL members except 
RTL5 and RTL8A to be predicted binding targets of 
specific PIWI-piRNA complexes (Figure 4A), with these 
interactions mapped in Figure 4B.
Associations of piRNAs with HNSCC-associated 
genomic alterations
In order to explore the larger mechanistic roles 
of our piRNAs in HNSCC, we correlated expression 
of all 30 HPV-dysregulated piRNAs to frequent 
somatic mutations and copy number variations (CNV) 
documented in HNSCC. Employing the Wilcoxon 
rank-sum test (p < 0.05), we identified upregulated 
piRNAs NONHSAT059231, NONHSAT077463, and 
NONHSAT144936 to display elevated expression 
in the presence of PTEN mutation (Figure 5A) and 
NONHSAT102574 and NONHSAT144936 to exhibit 
Figure 3: HPV-dysregulated piRNAs display (A) significant positive enrichment relative to PIWIL4 expression, (B) significant negative 
enrichment relative to RTL gene expression, and (C) significant positive enrichment relative to DNMT3L expression.
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increased expression in the presence of NOTCH mutation 
(Figure 5B). Finally, we identified downregulated 
piRNAs NONHSAT069719, NONHSAT108298, and 
NONHSAT123636 to exhibit significantly lowered 
expression in the presence of a variety of HNSCC-
associated CNVs (Figure 5C–5E).
Clinical significances of HPV-dysregulated 
piRNAs
Finally, we examined the clinical relevancies of all 
30 HPV-dysregulated piRNAs, using the Kruskal-Wallis 
test (p < 0.05) to assess their expression relative to a range 
of HNSCC clinical features.  Among all HPV16(+) patients 
with available clinical data (n = 43), we found upregulated 
piRNAs NONHSAT077364 and NONHSAT144936 to 
display significantly elevated expression with higher 
pathologic stage (Figure 6A).  Downregulated transcripts 
NONHSAT069719 and NONHSAT108298 displayed 
significantly decreased expression with higher histologic 
grade (Figure 6B).  Upregulated piRNA NONHSAT054230 
displayed significantly increased expression in presence 
of nodal extracapsular spread (Figure 6C).  We identified 
NONHSAT077364 to be significantly predictive of 
Figure 4: (A) miRanda target prediction reveals the potential for direct binding interactions between specific piRNAs and RTL family 
genes. (B) Conceptual map of miRanda-predicted piRNA-RTL binding interactions.
Figure 5: (A–B) Boxplots correlating expression of select HPV-dysregulated piRNAs to (A) PTEN mutation and (B) NOTCH mutation. 
(C–D) Boxplots correlating expression of select HPV-dysregulated piRNAs, (C) NONHSAT069719, (D) NONHSAT108298, and (E) 
NONHSAT123636, to common copy number variations in HNSCC (Wilcoxon rank sum, p < 0.05).
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patient outcome in both univariate and multivariate Cox 
regression analyses (Figure 6D, Supplementary Table 4).
In vitro validation of HPV-induced piRNA 
dysregulation
To verify the clinical dysregulation of our 
HPV-associated panel of piRNAs, we examined their 
endogenous expression in HPV(+) squamous cell 
carcinoma cell lines UM-SCC-47 and 93-VU-147T in 
comparison to their expression in HPV(–) normal human 
epithelial cell lines HaCaT and OKF6. We identified 
the piRNAs NONHSAT077364, NONHSAT102574, and 
NONHSAT128479, recognized for their clinical and 
mechanistic significances in HPV(+) HNSCC, to display 
their expected dysregulation in HPV(+) cancer vs. HPV(–) 
normal cell lines, in support of our computational findings 
(Figure 7).
DISCUSSION
HPV infection is the fastest growing cause 
of HNSCC today [1]. In this study, we conducted 
a comprehensive investigation of the clinical and 
mechanistic roles of piRNAs in HPV-associated HNSCCs.
 In order to perform a robust identification of HPV-
associated piRNAs, we analyzed piRNA differential 
expression between 77 HPV16(+) HNSCC and HPV(–) 
normal RNA-seq datasets from TCGA, separately 
evaluating HPV-induced piRNA dysregulation in smokers 
and in nonsmokers. We filtered for only the commonly 
dysregulated transcripts to eliminate the confounding 
effects of smoking status, and identified 30 HPV-altered 
piRNAs common between HPV(+) HNSCC and HPV(–) 
normal comparisons of smokers and nonsmokers.
Recent studies suggest that piRNAs execute their 
functionality by associating with PIWI proteins (PIWIL1-
PIWIL4), forming PIWI-piRNA complexes that play 
various regulatory roles [9, 12, 14]. Investigating relations 
between HPV-altered piRNAs and PIWI proteins, we 
identified our set of HPV-upregulated piRNAs in HNSCC 
to be positively correlated with PIWIL4 expression, 
suggesting that they may potentially interact with PIWIL4. 
While PIWIL4 remains relatively unexplored in cancer, 
past findings suggest that it is upregulated in breast cancer 
and that it promotes cell migration, decreases apoptosis, 
Figure 6: Boxplots indicating (A) upregulation of piRNAs NONHSAT077364 and NONHSAT144936 with higher pathologic stage, 
(B) dowregulation of piRNAs NONHSAT069719 and NONHSAT108298 with higher histologic grade, and (C) upregulation of 
NONHSAT054230 with presence of nodal extracapsular spread. (D) Kaplan-Meier curve depicting survival outcomes based on relative 
high and low expression of NONHSAT077364.
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and mildly increases proliferation, although whether or not 
these events occur through a piRNA-mediated mechanism 
remains unclear [15].
PIWI-piRNA complexes are thought to be 
primarily involved in targeted gene silencing, particularly 
retrotransposon silencing, through two primary 
mechanisms. First, the complexes may promote DNA 
methylation and therefore silencing of transposable 
elements by binding to transposon sequences (through 
piRNA-DNA complementarity) and guiding DNA 
methyltransferases to these sequences [16, 17].  Our 
analyses indicated a positive correlation in expression 
between HPV-upregulated piRNAs and DNMT3L, a 
protein essential for DNA methylation [13], suggesting 
that this mechanism may be important in piRNA-
mediated retrotransposon silencing.  Second, the PIWI-
piRNA complex may post-transcriptionally silence 
genes, including, but not limited to, retrotransposons, 
by direct binding of the piRNA to specific mRNA 
sequences, followed by PIWI protein-mediated cleavage 
or deadenylation and degradation of the mRNA [18].
As the specific interactions between piRNAs 
and retrotransposons in any malignancy remain 
virtually unexplored, we investigated the relationship 
between HPV-altered piRNAs and retrotransposon 
and retrotransposon-like gene expression in HNSCC. 
We determined a negative correlation between HPV-
upregulated piRNA expression and expression of six 
genes in the retrotransposon-like family RTL, matching 
our expectations from piRNA-induced repression. While 
the RTL family itself is not comprised of retrotransposons, 
previous studies suggest RTL genes to share homology 
with Ty3/gypsy retrotransposons but to have lost their 
ability to retrotranspose, suggesting that RTL genes may 
have structural similarities to retrotransposons that allow 
them to be targeted by piRNAs [19, 20]. piRNA target 
analysis suggested specific HPV-upregulated piRNAs to 
display significant sequence complementarily to all except 
two of the six correlation-relevant RTL genes, namely 
RTL1, RTL3, RTL6, and RTL8B. Interestingly, RTL genes 
seem to play opposing roles in carcinogenesis. RTL6 is 
a close derivative of RTL7 which has been recognized 
for its downregulation in pancreatic and gastric cancers 
and therefore likely acts as a tumor suppressor [21]. By 
contrast, RTL1 has been documented for its upregulation 
in hepatocellular carcinoma which suggests that it 
functions as an oncogene [22]. This suggests that while 
piRNAs may suppress RTL gene expression through either 
of the two mechanisms described above, more potent 
regulators may interfere with or oppose these interactions.
Next, we attempted to explore the role of our 
piRNAs in the bigger context of HPV-related HNSCC 
pathogenesis, examining correlations of HPV-dysregulated 
piRNAs with common mutations and copy-number 
variations in HNSCC.  We identified NONHSAT059231, 
NONHSAT077364, and NONHSAT144936 to associate 
with mutations in the tumor suppressor gene 
PTEN, a negative regulator of the Akt pathway that 
suppresses apoptosis and increases cell survival and 
has been found downregulated in 30% of HNSCCs 
[23].  Reduced expression of HPV-downregulated piRNA 
NONHSAT069719 also correlated with deletion of 
10q23.3, the locus of the PTEN gene [24]. Interestingly, 
PTEN deficiency has been associated with an HPV-
mediated mechanism, whereby HPV16 activates EGFR 
resulting in PTEN inactivation, which may in part be 
modulated by our piRNAs [25, 26].
In addition, NONHSAT102574 and NONHSAT 
144936 associated with mutations in NOTCH, a gene 
known to function primarily as a tumor suppressor in 
HNSCC [27]. In particular, loss-of-function mutations 
in NOTCH have been found to generate truncated 
proteins lacking the ankyrin repeat domain, crucial for 
transactivation for target genes and thought to contribute 
to HNSCC progression [28]. NONHSAT069719 and 
NONHSAT123636 both correlated with amplification 
of 1q36.2, the locus of mTOR, an oncogene that has 
frequently been found upregulated in HNSCCs [29, 
30].  Overactivation of the Akt pathway, perhaps due to 
loss of the regulatory functions of PTEN as mentioned 
above, may also play a role in mTOR overactivation, as 
mTOR is a downstream effector of Akt, and may further 
Figure 7: qRT-PCR verifies dysregulation of NONHSAT077364, NONHSAT102574, and NONHSAT128479 in HPV(+) 
cancer vs. HPV(–) normal cell lines. (Student’s t-test; **p < 0.01). 
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contribute to tumorigenesis. While the exact mechanisms 
by which piRNAs associate with well-documented 
HNSCC-associated aberrations remains to be elucidated, 
our findings suggest piRNAs to have far-reaching roles 
in HPV-induced tumorigenesis going well-beyond the 
implications of their direct, smaller-scale interactions.
We examined the clinical significances of our 
HPV-altered piRNAs in HNSCC to evaluate whether 
they have large-scale relevancies to tumor pathogenesis 
and progression. We found NONHSAT077364 and 
NONHSAT144936 to associate with pathologic stage, 
NONHSAT069719 and NONHSAT108298 with histologic 
grade, and NONHSAT054230 with nodal extracapsular 
spread, in a manner consistent with their direction of 
dysregulation in HPV-associated HNSCCs. These findings 
suggest that directionally specific piRNA alterations are 
significant in tumor pathogenesis and progression, either by 
playing a role in cancer induction or being a result of cancer 
induction.  Our previous study of smoking-induced piRNA 
dysregulation in HNSCC implicated NONHSAT077364, 
NONHSAT069719, and NONHSAT108298 in smoking-
induced oncogenesis as well, suggesting that these 
piRNAs may be generally implicated in HNSCCs [11]. 
To the best of our knowledge, all 5 transcripts remain 
previously unrecognized for clinical functionality in any 
malignancy, and NONHSAT144936 and NONHSAT054230 
are completely novel.  Lastly, we found NONHSAT077364, 
NONHSAT102574, and NONHSAT128479 to be 
consistently upregulated in HPV(+) cancer vs. HPV(–) 
normal cell lines, consistent with our expected clinical 
dysregulation, verifying the potential of these transcripts to 
significantly modulate HPV-related HNSCC.
At present, rigorous studies on PIWI-interacting 
RNA function are lacking, with significantly limited 
knowledge on their functionality in HPV-induced HNSCC 
or mechanistic involvement in malignant transformation. 
We believe our findings to shed novel insights into crucial 
roles of piRNAs in regulating both small- and large-scale 
cellular interactions and ultimately modulating clinical 
phenotypes in HPV-induced HNSCC.
MATERIALS AND METHODS
RNA-seq datasets and clinical data
MapSplice-aligned TCGA BAM files were obtained 
from the UCSC Cancer Genomics Hub (https://cghub.ucsc.
edu/) on 11 March 2015. To investigate piRNA expression, 
we downloaded RNA-seq datasets for all 77 HPV16(+) 
HNSCC and HPV(–) Normal head and neck tissue samples. 
The TCGA barcodes for all patients whose datasets were 
used in this study are provided in Supplementary Table 1.
Patient clinical data, including smoking status, were 
downloaded from the TCGA Data Portal on 20 March 2015 
(https://tcga-data.nci.nih.gov/tcga/findArchives.htm).
piRNA expression analysis
piRNA read counts were generated from sequencing 
datasets via BEDtools coverageBed (https://github.com/
arq5x/bedtools2) using piRNA annotation files. The 
piRNA BED file containing 27,127 piRNA transcripts 
was obtained from NONCODEv4 (http://www.bioinfo.
org/NONCODEv4/), a database integrating ncRNA data 
from RefSeq, Ensembl, and published literature. Read 
count tables were imported into edgeR v3.0 (http://www.
bioconductor.org/packages/release/bioc/html/edgeR.html), 
and lowly expressed piRNAs were filtered from the 
analysis. Following TMM normalization, pairwise 
comparisons were applied to identify significantly 
differentially expressed piRNAs between HPV16(+) and 
HPV(–) patient cohorts, as visualized in Figure 1A.
Association of ncRNA expression with tumor 
mutations and copy number aberrations
TCGA tumor mutation calls were obtained from 
mutation annotation files (maf) generated by the Broad 
Institute GDAC Firehose on 20 August 2016. We focused 
our analysis on 26 most frequently mutated genes in 
HNSCCs, as determined by whole exome sequencing 
of an independent tumor cohort by Stransky et al. 
(Supplementary Table 3A) [28]. Wilcoxon rank sum tests 
were employed to test for significant associations between 
piRNAs expression level (cpm) and mutational status.
Copy number variations for the TCGA tumors 
were obtained from the GISTIC2 pipeline in Firehose 
on 20 August 2016. Similarly, 73 significant (99% 
confidence) focal amplifications and deletions, along with 
all amplifications on 3q26, 8q24, and 11q13 (the most 
frequent CNVs in HNSCC), were analyzed for correlation 
to piRNAs using Wilcoxon rank sum tests (Supplementary 
Table 3B) [31].
Gene Set Enrichment Analysis (GSEA) to 
identify piRNA associations with mRNA 
expression
Available mRNA data for all HPV(+) HNSCC 
patients (n = 41) was obtained from TCGA on 2016 
June 28. The GSEA software from the Broad Institute 
(http://www.broad.mit.edu/gsea/) was used to identify 
enrichment of piRNA expression in relation to various 
mRNAs in all HPV(+) patients. The continuous mRNA 
expression values were used as phenotype labels, while 
the full set of 7385 piRNAs with available expression 
data were used to form the ranked list. Upregulated (n = 
24) and downregulated (n = 6) HPV-altered piRNAs were 
modeled as separate gene sets, independently examined 
for enrichment with respect to each mRNA. FDR < 25% 
is considered statistically significant as per GSEA [32].
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miRanda identification of piRNA targets
piRNA targets were identified by first determining 
potential target sites using sequence complementarity 
between each piRNA and the mRNA of interest, followed 
by an estimation of thermodynamic stability of RNA 
duplexes based on these alignments, by the miRanda 
algorithm (v 3.3a) (http://www.microrna.org/microrna), 
applying stringent alignment score (sc; ≥ 170) and energy 
threshold (en; ≤ –20.0 kcal/mol) [33].
Association of piRNA expression with clinical 
covariates and patient survival
Employing the Kruskal-Wallis test, we correlated 
piRNA expression to clinical variables using clinical data 
and piRNA expression values (in cpm), independently 
analyzing piRNA correlations in HPV16(+) HNSCC 
patients, HPV16(+) Smoking patients, and HPV16(+) 
Nonsmoking patients. Patients with no available 
information for a given characteristic were filtered from 
analyses involving that variable.
Candidate piRNAs were associated with patient 
survival using Cox proportional hazards models, with 
piRNA expression in tumors (cpm) modeled as a 
binary variable based on expression above or below 
the median.  Survival analyses were independently 
conducted on HPV16(+) HNSCC patients, HPV16(+) 
Smoking patients, and HPV16(+) Nonsmoking cohorts. 
We first performed univariate Kaplan-Meier analysis and 
univariate Cox regression analysis to identify candidates 
significantly associated with patient outcome (p < 0.05), 
and then performed multivariate Cox analysis to evaluate 
whether correlations were independent of clinical variables 
such as age (grouped into 10-year intervals), gender, and 
tumor grade and stage.
Cell culture
HPV(+) squamous cell carcinoma cell lines UM-
SCC-47, derived from the primary tumor of the lateral 
tongue of a male patient, and 93-VU-147T, derived from 
the upper aerodigestive tract, were generous gifts from Dr. 
Joseph Califano at the University of California, San Diego 
School of Medicine.  HaCaT, a spontaneously transformed 
immortal keratinocyte cell line derived from human skin, 
was a generous gift from Dr. Victor Nizet at the Center 
for Immunity, Infection, and Inflammation of the UC San 
Diego School of Medicine. These cells were cultured in 
DMEM supplemented with 10% fetal bovine serum, 2% 
penicillin/streptomycin, and 2% L-glutamate (GIBCO) 
and maintained at 37°C in a humidified 5% CO2/95% air 
atmosphere. 
Normal, early passage, oral epithelial cell line 
OKF6, derived from the floor of the mouth of genetically 
and clinically normal tissue, was a generous gift from 
the Rheinwald Lab at Harvard Medical School. The cells 
were cultured in keratinocyte serum-free media (Life 
Technologies) supplemented with EGF, bovine pituitary 
extract, 2% L-glutamine, 2% penicillin/streptomycin, 
and CaCl2 and maintained at 37°C in a humidified 5% 
CO2/95% air atmosphere.
Quantification of piRNA expression by qRT-PCR
Total RNA was isolated (Fisher Scientific) 
from cultured cells. cDNA was synthesized using the 
QuantiMiR™ RT kit (System Biosciences) as per the 
manufacturer’s instructions. Real-time PCR reaction 
mixes were created using FastStart Universal SYBR 
Green Master Mix (Roche Diagnostics), and run on 
a StepOnePlus™ Real-Time PCR System (Applied 
Biosystems) using the following program: 50°C for 2 
min, 95°C for 10 min, 95°C for 30 s, and 60°C for 1 min, 
for 40 cycles. Experiments were analyzed using the ddCt 
method. U6 primers and a Universal Reverse Primer 
were used from the QuantiMiR™ RT kit, and custom 
primers (Integrated DNA Technologies) were ordered 
using the following sequences: NONHSAT077364: 5′ 
– ACCTGATGTTACATTGTAGTGTGCTGATG – 3′, 
NONHSAT102574: 5′ – CATGATACTGTAAACGCTTT 
CTGATG – 3′, NONHSAT128479: 5′ – GGCTCTGTTGC 
GCAATGGATAGCGCAT – 3′.
Abbreviations
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